Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor agonist approved for treating hyperglycemia in patients with type 2 diabetes not adequately...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratner, Robert, Han, Jenny, Nicewarner, Dawn, Yushmanova, Irina, Hoogwerf, Byron J, Shen, Larry
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070629/
https://www.ncbi.nlm.nih.gov/pubmed/21410975
http://dx.doi.org/10.1186/1475-2840-10-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070629/
https://www.ncbi.nlm.nih.gov/pubmed/21410975
http://dx.doi.org/10.1186/1475-2840-10-22

Ejemplares similares